

RELEVANT EVENT

Pursuant to article 82 of the Spanish Securities Market Act (*Ley del Mercado de Valores*) and following Relevant Event number 183,256, of 4 March 2013, GRIFOLS, S.A. ("**Grifols**") notifies the acquisition of shares representing 32.93% of the economic and voting rights of Progenika Biopharma, S.A. ("**Progenika**") for a total amount of EUR 25 million. The acquisition involves the execution of the put and call options that certain shareholders of Progenika and Grifols granted to each other on 27 February 2013. As a consequence of the execution of this transaction, Grifols has increased its stake in Progenika to 89.08% of the share capital.

50% of the purchase price has been paid in exchange for 876,777 non-voting class B shares of Grifols, with a face value of EUR 0.05 each. The remaining 50% of the price has been paid in cash.

With this acquisition, Grifols reinforces once again its commitment to research and strengthens its Diagnostic Division.

In Barcelona, on 3 March 2016

Núria Martín Barnes
Secretary to the Board of Directors